Events

Retiro De Equipo (Recall) de HeartMate 3 Left Ventricular Assist System

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Abbott Medical Australia Pty Ltd.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    RC-2018-RN-00668-1
  • Clase de Riesgo del Evento
    Class I
  • Fecha de inicio del evento
    2018-06-01
  • País del evento
    Australia
  • Fuente del evento
    DHTGA
  • URL de la fuente del evento
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2018-RN-00668-1
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Further to the april 2018 safety alert communication (rc-2018-rn-00302-1) sent to surgeons in regards to heartmate 3 (hm3) outflow graft twist occlusions, abbott have identified the need for further clarification on the origin of the outflow graft twist, the persistent low flow alarm, additional recommendations for patient management and future mitigations to be implemented. abbott is aware that accumulation of an outflow graft twist may occur at any point post-implantation, which can reduce or stop pump flow. occlusion of the hm3 outflow graft often requires urgent surgical intervention.
  • Acción
    Abbott is advising they are investigating mitigations to prevent Outflow Graft twist occlusion. In the interim, Abbott recommends the following for HM3 patients: Existing Patients: - Surgeons should refer to the information provided in the Customer Letter for managing patients who have been implanted with HM3 New Patients: - During implant, when attaching the Outflow Graft to the Pump Cover, a clicking sound will be heard as the Screw Ring is tightened. Continue turning the Screw Ring clockwise until it comes to a complete stop and stops clicking. Firmly hand-tightening the Screw Ring may reduce the risk of Outflow Graft twisting by increasing the resistance to metallic Outflow Graft connector rotation. To avoid damaging the Outflow Graft assembly, do not use tools to tighten the screw ring. - The proposed clarification on Warning and additional Caution statement will be incorporated into the Instructions for Use

Device

HeartMate 3 Left Ventricular Assist System
  • Modelo / Serial
    HeartMate 3 Left Ventricular Assist System Catalogue Number: 106524INT LVAS KIT, HM3 ARTG Number: 300895(Abbott Medical Australia - HeartMate 3 LVAS Implant Kit Model 106524INT - Implantable ventricular circulatory assist system)
  • Clasificación del producto
    Cardiovascular Devices
  • Manufacturer
    Abbott Medical Australia Pty Ltd

Manufacturer

Abbott Medical Australia Pty Ltd
  • Empresa matriz del fabricante (2017)
    Abbott Laboratories
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DHTGA